CurrentBlue KCPolicy POL-PP-316

Thyroid Disease Testing

Defines when thyroid laboratory tests (TSH, free T4, T3, antibodies, thyroglobulin, etc.) are reimbursable for Blue KC members and describes tests that are not reimbursable; applies to professional and facility providers submitting claims.

Policy Summary

PayerBlue KC

PolicyThyroid Disease Testing

Policy CodePolicy POL-PP-316

Change TypeNo material change

Effective DateJul 1, 2025

Next Review DateJul 1, 202619d

Key ActionVerify member coverage and benefits prior to ordering thyroid testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Comprehensive test listComprehensive codes

Trimester-specific rangesPregnancy guidance

Cadence examplesMonitoring intervals

001Version

Coverage Criteria for Thyroid Testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Signs or symptoms of hypothyroidism: TSH testing to confirm or rule out primary hypothyroidism; free T4 (fT4) testing as follow-up to abnormal TSH; TSH and fT4 testing for suspected secondary hypothyroidism; monitoring for individuals treated for primary hypothyroidism with TSH and fT4 every 6 weeks after dosage change and annually if stable; for secondary hypothyroidism monitor with fT4 every 6 weeks after dosage change and annually if stable.

See Note 1 for symptom list

Signs or symptoms of hyperthyroidism: TSH testing to confirm or rule out overt hyperthyroidism; fT4 testing as follow-up to abnormal TSH; total T3 (TT3) or free T3 (fT3) testing to confirm a diagnosis of hyperthyroidism; fT4 testing to distinguish overt versus subclinical hyperthyroidism; monitoring after treatment with repeat TSH and fT4 every 8 weeks during treatment and annual monitoring after the first year for relapse risk or late-onset hypothyroidism.

See Note 2 for symptom list

Medications that interfere with thyroid function: Asymptomatic individuals prescribed drugs known to interfere with thyroid function: TSH testing annually, when dosage/medication changes, or if symptoms develop.

Individuals capable of becoming pregnant: TSH testing for individuals undergoing evaluation for infertility or who have experienced two or more pregnancy losses.

One-time screening for high-risk asymptomatic individuals: One-time TSH screening for asymptomatic individuals at high risk due to personal or family history of thyroid dysfunction, type 1 diabetes, or other autoimmune disease.

Thyroid or other endocrine disease/neoplasm: Testing for individuals with disease or neoplasm of the thyroid or other endocrine glands.

Chronic or acute urticaria: TSH testing may be reimbursable for individuals with chronic or acute urticaria.

Pediatric indications: TSH testing for pediatric individuals with short stature or failure-to-thrive; for hypothalamic-pituitary disease monitor TSH and fT4 biannually if <18 years and annually if ≥18 years.

Immune reconstitution therapy (IRT): TSH testing every 3 months with reflex fT4 and fT3 when TSH is abnormal for individuals undergoing IRT (e.g., alemtuzumab for MS, HIV on HAART, post allogeneic BMT/HSCT).

Pregnancy or postpartum with symptoms: For pregnant or postpartum individuals with symptoms of thyroid dysfunction, TSH and fT4 testing once every 4 weeks may be reimbursable; for pregnant/postpartum individuals diagnosed with hyperthyroidism, TT4, Tg-Ab, TRab, and TPOAb may be reimbursable.

See Note 3 for pregnancy laboratory reporting requirements

Thyroid cancer surveillance: Serum thyroglobulin and/or thyroglobulin antibody testing for detection of tumor recurrence, post-surgical evaluation, surveillance, and maintenance for differentiated thyroid carcinomas may be reimbursable.

Primary mitochondrial disease: Annual screening of TSH and fT4 for individuals diagnosed with primary mitochondrial disease.

Not reimbursable or limited testing

The following tests are explicitly indicated as not reimbursable in the policy unless otherwise listed above:

Tests not reimbursable: Testing for thyrotropin-releasing hormone (TRH) or thyroxine-binding globulin (TBG) to evaluate causes of hypo- or hyperthyroidism is not reimbursable; reverse T3, T3 uptake and total T4 testing are not reimbursable for situations not mentioned above; measurement of total T3 (TT3) and/or free T3 (fT3) and measurement of total or free T3 to assess levothyroxine dosing may not be reimbursable; routine thyroid testing for asymptomatic nonpregnant individuals during a general exam without abnormal findings may not be reimbursable.

Procedure Codes and Monitoring Intervals

Listed laboratory procedure codesCPT

80438	Thyrotropin releasing hormone (TRH) stimulation panel;1 hour (includes TSH x3)
80439	Thyrotropin releasing hormone (TRH) stimulation panel;2 hour (includes TSH x4)
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (e.g., RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
84432	Thyroglobulin
84436	Thyroxine; total
84439	Thyroxine; free
84442	Thyroxine binding globulin (TBG)
84443	Thyroid stimulating hormone (TSH)
84445	Thyroid stimulating immune globulins (TSI)

1–10 of 16

1/2

TSH monitoring frequency examples

Primary hypothyroidism monitoringTSH and fT4 every 6 weeks after a dosage change; annual monitoring if stable

Hyperthyroidism during treatmentRepeat TSH and fT4 every 8 weeks during treatment; annual monitoring after first year for relapse risk or late hypothyroidism

Pregnancy/postpartum with symptomsTSH and fT4 once every 4 weeks for pregnant or postpartum individuals with symptoms

Immune reconstitution therapy (IRT)TSH every 3 months with reflex fT4 and fT3 when TSH is abnormal

Hypothalamic–pituitary disease (pediatric vs adult)Biannually if <18 years; annually if ≥18 years

Provider Responsibilities and Billing Guidance

Prior Authorization

Verify member benefits before testing

Coverage for thyroid testing is determined by the member's benefit eligibility and claims adjudication at the time of service. Verify member coverage and benefits prior to ordering or performing thyroid laboratory tests to confirm reimbursement eligibility.

Step Therapy

No step therapy program described

No step-therapy or sequencing prior-authorization program is specified in this policy. The document provides monitoring intervals (e.g., TSH/fT4 monitoring cadence) but does not require trials of other tests or therapies before coverage.

Documentation Required

Laboratory reporting requirement for pregnancy

When testing pregnant or postpartum individuals, use laboratories that provide trimester-specific normal ranges for the assay(s). The policy states free T4 (fT4) is the preferred test; total T4 (TT4) may be used if trimester-specific fT4 ranges are unavailable or if TSH and fT4 are discordant.

Perform hormone measurements only at labs with trimester-specific reference ranges.
Prefer fT4 for pregnancy testing; use TT4 when trimester-specific fT4 ranges are unavailable or results are discordant.

Denial Risk

Common denial triggers

Tests that are explicitly not reimbursable in situations not listed include reverse T3, T3 uptake and total T4; measurement of total or free T3 to assess levothyroxine dosing may also not be reimbursable. Routine screening of asymptomatic nonpregnant individuals during a general exam without abnormal findings may not be reimbursable and is a common cause of denial.

Reverse T3 (84482), T3 uptake (84479) and total T4 (84436) are not reimbursable except where specifically indicated.
Measurement of total or free T3 (84480/84481) to assess levothyroxine dose may not be reimbursable.
Testing asymptomatic nonpregnant individuals during general exams without abnormal findings may be denied.

Definitions

Thyroid disease

Thyroid disease (definition)Conditions causing hypothyroidism, hyperthyroidism, goiter, thyroiditis, and thyroid tumors

Scope of thyroid function testsUsed to assess thyroid function, monitor treatment, and screen for subclinical or undiagnosed thyroid dysfunction

Terminology noteTerms such as male and female are used when necessary to refer to sex assigned at birth

Male/female

Definition of usageTerms male and female refer to sex assigned at birth when necessary

ContextUsed throughout the policy for clarity in clinical indications and testing eligibility

ApplicabilityApplied where sex-based reference ranges or clinical criteria are relevant

OpenPayer

Thyroid Disease Testing

Coverage Criteria for Thyroid Testing

Procedure Codes and Monitoring Intervals

Provider Responsibilities and Billing Guidance

Background

Definitions